Disc Medicine (IRON) Stock Price, News & Analysis

Company Overview

Disc Medicine, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of small‐molecule therapies for rare genetic diseases driven by oxidative stress and mitochondrial dysfunction. The company’s proprietary platform enables the rapid identification and optimization of compounds designed to restore cellular redox balance in underserved patient populations. Its lead programs target debilitating conditions such as Friedreich’s ataxia and Fanconi anemia, where dysregulated iron metabolism and mitochondrial injury are central to disease pathology.

Leveraging a combination of structure‐based design and phenotypic screening, Disc Medicine has advanced its lead candidate through IND‐enabling studies and into early human trials. Preclinical programs also include novel compounds aimed at neurodegenerative and mitochondrial disorders, reflecting the company’s commitment to expanding its pipeline across multiple indications with significant unmet medical need. In parallel, Disc Medicine maintains an active research collaboration network with leading academic institutions to validate novel therapeutic hypotheses.

Founded in 2017 and headquartered in Cambridge, Massachusetts, Disc Medicine draws on deep expertise in redox biology and drug discovery. Since its inception, the company has secured strategic collaborations and licensing agreements that broaden its access to complementary technologies and accelerate its development timelines. Its teams operate from state‐of‐the‐art laboratories in the greater Boston area, supporting both in vitro and in vivo studies that underpin its clinical-stage assets.

The executive leadership team at Disc Medicine comprises seasoned biotech and pharmaceutical professionals with extensive experience in clinical development, regulatory affairs and commercial strategy. Together, they guide the company’s efforts to translate pioneering science into targeted therapies, with the aim of delivering meaningful treatment options to patients worldwide. Disc Medicine continues to expand its organizational capabilities, positioning itself for future growth across North America, Europe and Asia.

Key Stats

• Today's Range: $53.17 to $55.26
• 50-Day Range: $42.71 to $55.00
• 52-Week Range: $30.82 to $68.73
• Volume: 218,300 shs
• Average Volume: 339,300 shs
• Market Capitalization: $1.90 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $96.70
• Consensus Rating: Buy

Disc Medicine Stock Analysis - MarketRank™

Disc Medicine scored higher than 62% of companies evaluated by MarketBeat, and ranked 1183rd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Disc Medicine has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Disc Medicine has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Disc Medicine are expected to decrease in the coming year, from ($4.07) to ($5.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Disc Medicine is -13.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Disc Medicine is -13.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Disc Medicine has a P/B Ratio of 3.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.18% of the float of Disc Medicine has been sold short.

Short Interest Ratio / Days to Cover

Disc Medicine has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in Disc Medicine has recently increased by 3.23%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Disc Medicine does not currently pay a dividend.

Dividend Growth

Disc Medicine does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.18% of the float of Disc Medicine has been sold short.

Short Interest Ratio / Days to Cover

Disc Medicine has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in Disc Medicine has recently increased by 3.23%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.54

News Sentiment

Disc Medicine has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Disc Medicine this week, compared to 6 articles on an average week.

Search Interest

Only 4 people have searched for IRON on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

MarketBeat Follows

4 people have added Disc Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $693,794.00 in company stock.

Percentage Held by Insiders

Only 4.24% of the stock of Disc Medicine is held by insiders.

Percentage Held by Institutions

83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IRON Stock Analysis - Frequently Asked Questions

How have IRON shares performed this year?

Disc Medicine's stock was trading at $63.40 at the beginning of the year. Since then, IRON stock has decreased by 13.7% and is now trading at $54.7450.

How were Disc Medicine's earnings last quarter?

Disc Medicine, Inc. (NASDAQ:IRON) issued its quarterly earnings data on Wednesday, May, 7th. The company reported ($1.02) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by $0.03.

How do I buy shares of Disc Medicine?

Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Disc Medicine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/03/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IRON
• CIK: 1816736
• Web: www.discmedicine.com
• Phone: 617-401-4400
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $96.70
• High Stock Price Target: $132.00
• Low Stock Price Target: $75.00
• Potential Upside/Downside: +76.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.09
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$109.36 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -22.61%
• Return on Assets: -21.07%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 37.65
• Quick Ratio: 37.65

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.85 per share
• Price / Book: 3.69

Miscellaneous

• Outstanding Shares: 34,630,000
• Free Float: 33,166,000
• Market Cap: $1.90 billion
• Optionable: Not Optionable
• Beta: 0.76